Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

MCLEOD, DAVID G., IVERSEN, PETER, SEE, WILLIAM A., MORRIS, THOMAS, ARMSTRONG, JON, WIRTH, MANFRED P., the Casodex Early Prostate Cancer Trialists’ Group · 2006 · BJU International

Abstract

OBJECTIVE: To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer. PATIENTS AND METHODS: The EPC programme comprises three randomized, double‐blind, placebo‐controlled trials designed for combined analysis. Following standard care, 8113 men with localized (T1‐2, N0/Nx) or locally advanced (T3‐4, any N; or any T, N+) prostate cancer (all M0) received oral bicalutamide 150 mg once daily or oral placebo. The primary endpoints were progression‐free survival (PFS) and overall survival. RESULTS: The large EPC trial programme is defining men who benefit or do not from early or adjuvant antiandrogen therapy. At a median follow‐up of 7.4 years, in localized disease there is no benefit to PFS by adding bicalutamide to standard care, and there is a trend (hazard ratio, HR, 1.16; 95% confidence intervals, CI, 0.99–1.37; P = 0.07) towards decreased survival in patients otherwise undergoing watchful waiting. However, in locally advanced disease, bicalutamide significantly improved PFS irrespective of standard care. Bicalutamide significantly improved overall survival in patients receiving radiotherapy (HR 0.65; 95% CI 0.44–0.95; P = 0.03); this was driven by a lower risk of prostate cancer‐related deaths. Bicalutamide produced a trend towards improved overall survival in patients with locally advanced disease otherwise undergoing watchful waiting (HR 0.81; 95% CI 0.66–1.01; P = 0.06). No survival difference was evident in the prostatectomy subgroup. CONCLUSIONS: This ongoing programme is clarifying the role of early or adjuvant antiandrogen therapy in prostate cancer. Patients with localized disease do not appear to derive clinical benefit from added bicalutamide. However, adding bicalutamide 150 mg to standard care provides significant clinical benefits in patients with locally advanced prostate cancer, irrespective of primary therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-410x.2005.06051.x

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 277

Metadata

Authors
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group
Venue
BJU International
Publisher
Wiley
Published
2006-01-17
Volume
97
Issue
2
Pages
247-254
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W2117299097
Cited by
277
References
21
FWCI
21.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. https://app.cochat.ai/papers/10.1111/j.1464-410x.2005.06051.x
The paper
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group. (2006). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International. https://doi.org/10.1111/j.1464-410x.2005.06051.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.